Rosutin EZ Tablet 5 mg + 10 mg is a combination therapy that brings together Rosuvastatin and Ezetimibe, offering a comprehensive approach to managing elevated cholesterol and reducing cardiovascular risk. This fixed-dose formulation is designed for patients who require more intensive lipid-lowering therapy than monotherapy can provide. It effectively reduces LDL cholesterol, total cholesterol, and triglycerides, while modestly increasing HDL cholesterol, thereby improving overall cardiovascular health.

The combination targets cholesterol through two complementary mechanisms: Rosuvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver, while Ezetimibe inhibits intestinal absorption of cholesterol, lowering the amount of cholesterol entering the bloodstream. By acting on both production and absorption, Rosutin EZ provides more significant lipid-lowering effects than either agent alone.

This tablet is indicated for heterozygous familial and non-familial hypercholesterolemia, mixed dyslipidemia (Fredrickson Type IIa and IIb), and as adjunct therapy for the primary prevention of cardiovascular disease in patients who do not achieve target LDL-C goals with statin monotherapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Rosutin EZ Tablet 5 mg + 10 mg is indicated for:

• Heterozygous Hypercholesterolemia (Familial and Non-familial)

• Mixed Dyslipidemia (Fredrickson Type IIa and IIb)

• Primary prevention of cardiovascular disease in high-risk patients

• Patients not achieving LDL-C targets with statin alone

Therapeutic Class

Combination Therapy: Statin + Cholesterol Absorption Inhibitor

Pharmacology

Rosuvastatin is a selective HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver, upregulates LDL receptors, and promotes clearance of LDL particles.

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, preventing absorption of dietary and biliary cholesterol. This dual mechanism reduces LDL cholesterol more effectively than either drug alone and offers additive benefits for patients with persistent hypercholesterolemia.

Dosage and Administration

• Adults: 5 mg Rosuvastatin + 10 mg Ezetimibe once daily, orally

• The tablet can be taken with or without food, at any time of day

• Dose adjustments may be required based on response, tolerability, and patient-specific factors

• Regular lipid monitoring is recommended to assess efficacy and guide therapy

Special Populations:

• Pediatric use: Safety and efficacy in children have not been established

• Elderly patients: May require monitoring for muscle or liver-related effects

Drug Interactions

• Cyclosporine: Increases Rosuvastatin exposure; use with caution

• Gemfibrozil: May increase risk of myopathy; avoid if possible

• Warfarin: Monitor INR closely

• Other lipid-lowering therapies (fibrates, niacin): Increased risk of skeletal muscle effects

• Ezetimibe has minimal interactions, but combined therapy with statins requires monitoring for liver and muscle toxicity

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Hypersensitivity to Rosuvastatin, Ezetimibe, or any component of the formulation

• Active liver disease or unexplained persistent elevations in hepatic transaminases

• Pregnancy or breastfeeding

• Pediatric patients under recommended age

Side Effects

• Common: Headache, myalgia, fatigue, abdominal pain, constipation, nausea

• Rare: Muscle-related effects (myopathy, rhabdomyolysis) or liver enzyme elevations

• Patients should report unexplained muscle pain or weakness immediately

Pregnancy and Lactation

• Not recommended during pregnancy or breastfeeding

• Use only if clearly necessary, under physician supervision

Precautions and Warnings

• Monitor liver function before starting therapy and periodically thereafter

• Be alert for skeletal muscle toxicity, especially in elderly patients or those on interacting medications

• Patients with renal impairment may require dose adjustments

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.

Mode of Action

• Rosuvastatin: Inhibits HMG-CoA reductase, decreasing cholesterol synthesis and enhancing LDL clearance

• Ezetimibe: Inhibits intestinal cholesterol absorption, lowering the cholesterol delivered to the liver

• Combined effect: Significant reduction in LDL-C, total cholesterol, and triglycerides, supporting cardiovascular risk reduction.